Late Night with LRIG

Cell X Technologies - The Cell X Platform for Cell Process Automation - High Content Imaging and Colony Picking

Monday, February 5
6:00 PM - 6:40 PM
Location: Room 8

Cell X Technologies has developed the Cell X platform as resource for cell source management and quality control.

Cells are the core resource for biological products & bio-manufacturing. No new tissue is formed without cells.

Cell populations from different donors/tissues vary highly in concentration, prevalence, & biological potential. The challenge: managing this variation in design, fabrication, & quality control of all cell therapies.

Innovators of new therapies must have control over cell sources, quality, & biological attributes of cells entering/ leaving the processing chain. Quantitative metrics must be used to define critical quality attributes (CQAs) of cell sources and cell products.

The Cell X Platform enables you to:

Know what you have - based on quantitative ASTM imaging standards.
Pick what you want - using precision microfluidics.
Show what you’ve done - archiving images of every cell source history.
Know how to do it again - by defining automated operator independent protocols.

In providing these functions, Cell X enables users to:
1. Improve the reproducibility and the quality of the cells they include in their research or products.
2. Reduce the variation and cost of manufacturing associated with variation in starting materials (cell sourcing decisions).
3. Improve process documentation and controls, eliminating operator bias.
4. Define quantitative imaging-derived in-process quality attributes and CQA-based metrics for release criteria their unique cells or products.

George F. Muschler

Orthopaedic Surgeon and Director of Regenerative Medicine - Cleveland Clinic, Lerner Research Institute
Cell X Technologies

Dr. Muschler is an Orthopaedic Surgeon and Clinician-Scientist at the Cleveland Clinic.
His clinical practice integrates complex adult reconstructive surgery, joint preservation, and bone and cartilage repair. Dr. Muschler also leads a research laboratory focusing on stem and progenitor cell biology, aging, tissue engineering and regenerative medicine, which has earned continuous federal funding for 18 years.

Dr. Muschler served as Vice Chair of the Cleveland Clinic Department of Bioengineering (2004-2013); Director of the Orthopaedic Research Center (2005-2013, embracing clinical and basic musculoskeletal research across 13 departments), and as Vice Chair of the Orthopaedic and Rheumatologic Institute (2007-2013).

Dr. Muschler was the leader in the development of several multi-institutional collaborative translational networks, founding and leading the Ohio-based Clinical Tissue Engineering Center (2005-2012), and serving as the founding Co-Director of the Armed Forces Institute of Regenerative Medicine (AFIRM) (2008-2011), a national network funded by the Department of Defense and dedicated to the accelerated development of improved therapies to serve wounded warriors.

Dr. Muschler earned his undergraduate degree in Chemistry at the University of Illinois in Champaign-Urbana and his M.D. at Northwestern University School of Medicine in Chicago, Illinois. He completed his residency in Orthopaedic Surgery at the University of Texas Southwestern, Dallas, Texas, and fellowships at Memorial Sloan Kettering Cancer Center and the Hospital for special Surgery in New York.


Send Email for George Muschler


Cell X Technologies - The Cell X Platform for Cell Process Automation - High Content Imaging and Colony Picking


Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Cell X Technologies - The Cell X Platform for Cell Process Automation - High Content Imaging and Colony Picking